Company ProfilePremium

Panjin Zhongrun High Performance Polymers Co., Ltd.

Company Profile Analysis

盘锦中润特塑有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Panjin Zhongrun High Performance Polymers Co., Ltd. - Company showcase

Year Founded & Workforce

2009

Panjin Zhongrun High Performance Polymers Co., Ltd. logo

Panjin Zhongrun High Performance Polymers Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Panjin Zhongrun High Performance Polymers Co., Ltd. Overview

Panjin Zhongrun High Performance Polymers was one of China's early private attempts to make polyetheretherketone (PEEK) resin domestically at commercial scale. It was founded in 2009 in the Panjin petrochemical cluster of Liaoning Province. It used the nucleophilic polycondensation route developed at Jilin University and held four synthesis patents covering polysulfone-family resins and copolymerised PEEK. The company built a Phase 1 plant with a nameplate capacity of up to 1,000 t/y and marketed its resin under the CoPEEK brand. By 2012 it was pursuing export markets through an exclusive European distribution agreement with Hamburg-based Bieglo. Its claimed capacity matched that of the eventual domestic leader, Zhongyan. Its commercial traction, however, appears to have been limited: industry directories in 2017 described its operating rate as unknown. By December 2022, a competitor's regulatory filing reported its business licence as revoked. The company is best understood today as a cautionary case study in China's PEEK import-substitution drive, not as an operating competitor.


What the company did

Panjin Zhongrun was a resin-synthesis company. It sat in the mid-stream polymerisation step of the PEEK value chain. That step converts aromatic monomers into polymer powder and pellets. The monomers are principally 4,4'-difluorobenzophenone (氟酮, "fluoroketone") and hydroquinone. The reaction uses a carbonate condensing agent in a high-boiling solvent, typically diphenyl sulfone. The company's own published description, as reproduced in a 2017 Aibang directory, emphasised three things:

Four synthesis patents: covering different methods of producing polysulfone (PSU), polyethersulfone (PES), polyether ether sulfone (PEES), biphenyl polyether ether sulfone (PPSU), and copolymerised PEEK (CoPEEK).

  • A Phase 1 project of 1,000 t/y of CoPEEK production capacity.

  • Use of the Jilin University nucleophilic synthesis route.

A separate Chinese industry article (China Advanced Materials Industry Expo, undated) stated that the 1,000 t/y CoPEEK unit had entered production and sales. It also claimed that this capacity ensured consistent CoPEEK quality.

Company's own description from its latest annual report

Not available. As a private limited company, Panjin Zhongrun publishes no annual report. PRC companies must file an annual report summary with the State Administration for Market Regulation (SAMR) via the National Enterprise Credit Information Publicity System. Revocation of a business licence often follows failure to make these filings.

Business model and revenue model

DimensionCharacterisationEvidence quality
Revenue modelProduct sales (resin powder and pellets); no service, subscription, or licensing revenue identifiedModerate (inferred from product listings and distributor agreement)
Product vs. service mix~100% product (estimated qualitatively; no figures disclosed)Low
LicensingHeld 4 synthesis patents; no evidence of out-licensingLow
Go-to-marketDirect domestic sales plus third-party distribution abroad (Bieglo, Europe, from 2012)Moderate
Pricing posturePositioned on price competitiveness versus Western incumbents, while arguing that value-in-use, not price, decides customer choiceModerate (Plasteurope interview with sales director Steven Xu, 2012)

Value-chain position

Value-chain stageTypical playersPanjin Zhongrun role
Monomers (fluoroketone, hydroquinone)Jiangsu Xinhan, Yingkou Xingfu, Zhongxin Fluorine; Eastman/Mitsui (photo-grade hydroquinone)Buyer (not disclosed which suppliers)
Polymerisation (resin synthesis)Victrex, Syensqo/Solvay, Evonik, Zhongyan, Jida Tesu, PengfulongCore activity
Compounding (GF/CF/wear grades)Resin makers plus compoundersLimited; only unreinforced CoPEEK grades identified
Stock shapes (rod, sheet, tube)Ningbo Zheneng, Jiangsu Junhua, Ensinger etc.Customer segment
Component fabrication / OEMElectronics, auto, oil & gas, medicalEnd markets

Customer types and end-markets (independent characterisation)

The company did not disclose customer lists. By analogy with Zhongyan's disclosed customer base (December 2022 IPO filing), a Chinese PEEK resin producer of this era would mainly sell to the following groups:

  1. Stock-shape (profile) processors. These are converters of rod, sheet and tube. They made up about 66–71% of Zhongyan's revenue in 2019–2021.

  2. Component moulders and machinists. These include makers of seals, bearings, compressor valve plates, wafer carriers and similar parts.

  3. Traders and distributors, especially for export.

End-markets for PEEK at the time included electronics and semiconductors, industrial machinery, oil & gas and energy, automotive, aerospace and medical. Panjin Zhongrun's single verified grade was low-viscosity, unreinforced, rated UL 94 V-0, and also offered as powder. That profile suggests it targeted injection-moulding and coating or compression-moulding applications. Whether it achieved meaningful penetration in any end-market is not publicly disclosed.

Strategy

Stated strategy (historical, 2012)

No annual report or investor-day material exists. The only articulated strategy comes from the company's 2012 statements to the trade press, paraphrased here:

  1. International expansion through distribution. The company signed with Bieglo to extend its reach in Europe, focusing on German-speaking markets and Belgium.

  2. Competitive pricing paired with value-in-use. It positioned CoPEEK as cheaper than incumbent offerings, while arguing that customers ultimately choose on the added value of the material.

  3. Platform breadth through patents. It held synthesis patents spanning the PAEK and polysulfone families, implying an intention to broaden into PSU, PES, PEES and PPSU.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

None identified. No partnerships, launches, ESG commitments, cost programmes or guidance from the company were found for this period. This is consistent with the revoked-licence status reported in December 2022.

Medium-term targets and guidance

Not publicly disclosed and not applicable.

Products & Services

Verified products

ProductDescriptionKey specificationsTarget customerLaunch / latest versionPricingSource
CoPEEK 085GSemi-crystalline, low-viscosity, unreinforced polyetheretherketoneUnfilled; low melt viscosity; flame rating UL 94 V-0 (per supplier listing); also available as powderInjection moulders; powder-coating and compression-moulding users (inferred from low viscosity and powder form)c. 2011–2012 (inferred from European launch in 2012)Not disclosed; marketed on price competitivenessSpecialChem/Omnexus supplier page; Plasteurope (2012)
CoPEEK powder formPowder version of the aboveAs aboveCoating and moulding processors——SpecialChem/Omnexus
CoPEEK grade family (general)Unspecified range of "CoPEEK grades" distributed in Europe by Bieglo—European processors, especially German-speaking markets and Belgium2,012—Plasteurope (2012)
PolymerBasisCommercial evidence
Polysulfone (PSU)Synthesis patent (1 of 4 patents covering multiple routes)None found
Polyethersulfone (PES)Synthesis patentNone found
Polyether ether sulfone (PEES)Synthesis patentNone found
Biphenyl polyether ether sulfone (PPSU)Synthesis patentNone found
Copolymerised PEEK (CoPEEK)Synthesis patentCommercialised (see 5.1)

What "CoPEEK" means (analyst note)

The "Co-" prefix indicates a copolymerised PEEK. In this approach, part of the standard monomer set is replaced with a comonomer to change crystallinity, glass-transition temperature, or processability. The company has not publicly disclosed the exact comonomer chemistry. The 2012 interview stressed value-added performance as well as price, which suggests the copolymer was positioned as a differentiated grade and not a pure commodity substitute. This is analyst inference and has not been confirmed by the company.

Missing elements versus peers

Zhongyan disclosed 52 grades across six product series in its IPO prospectus: coarse powder (P), fine powder (PF), pellets (G), glass-fibre reinforced (GL), carbon-fibre reinforced (CA) and wear-resistant (FC). Compared with this, Panjin Zhongrun's verifiable catalogue is very narrow. No reinforced compounds, medical grades, film, fibre, or stock-shape products have been identified.

Financial Narrative

Disclosure position

No financial statements of Panjin Zhongrun High Performance Polymers have ever been publicly disclosed. The company is private, never filed with a securities regulator, and is reported to have a revoked business licence. Every financial metric below is therefore not publicly disclosed. No estimates are given, in line with the no-fabrication rule.

Some 2025–2026 market-research tables of contents (e.g., Gelonghui-hosted reports) include section headings promising this company's "sales, volume, price and gross margin 2021–2026." These are generic report templates. They should not be treated as company disclosures.

Ratios

ROE, ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and the cash conversion cycle are all not publicly disclosed and not computable.

Peer financial reference: what a 1,000 t/y Chinese PEEK producer earns

The closest disclosed analogue gives context for the economics Panjin Zhongrun would have faced. Jilin Zhongyan ran the same Jilin-University-derived nucleophilic route at the same 1,000 t/y nameplate. Its figures are shown below. These are Zhongyan's figures, not Panjin Zhongrun's.

Source: Da Hua CPA / Zhongyan IPO inquiry response, SSE disclosure, 7 Dec 2022 (RMB 10k figures converted to RMB M).

Commentary. Even the domestic leader, which had established customers, used only 34–55% of its 1,000 t/y polymerisation capacity in 2019–2021. It generated roughly RMB 110–200 M of revenue. The filing put Chinese PEEK prices at RMB 300,000–600,000 per tonne. For Panjin Zhongrun to cover the fixed costs of a 1,000 t/y polymerisation plant, it would have needed comparable volumes. The 2017 directory, however, could not confirm any operating rate at all. The likely conclusion, which is analyst inference and has not been confirmed, is that the plant ran far below the scale needed to cover its fixed costs. That would be consistent with the later licence revocation.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Implied Operating Unit Details

Implied operating unitContentsStatus

PAEK resins (CoPEEK)

Copolymerised PEEK powder and pellets (e.g., CoPEEK 085G)

Commercialised c. 2011–2012; current status inactive

Polysulfone-family resins (PSU / PES / PEES / PPSU)

Patented synthesis methods

No evidence of commercial production

Cash Flow and Operating Metrics (t)

Metric (Zhongyan, peer benchmark)FY2019FY2020FY2021

Operating revenue (CNY Mn)

111.88158.18203.01

Coarse-powder capacity (t)

1,0001,0001,000

Coarse-powder output (t)

342.95541.45549.98

Coarse-powder capacity utilisation (%)

34.2954.1455.00

Operating cash flow (CNY Mn)

0.2721.4937.79

Capital Markets

MetricFY2021

Item

Status

Analyst consensus

No coverage

Credit ratings (Moody's / S&P / Fitch)

Not rated

Domestic credit ratings

None identified

Analyst Conclusions

Management guidance and consensus

None exists. There is no management guidance, no consensus, and no analyst coverage.

Bull case (revival or asset-value scenarios)

  1. The asset could be monetised. China's PEEK demand has grown from 80 t (2012) to about 1,980 t (2021). New entrants plan more than 6,000 t/y of capacity. A permitted polymerisation site and patents in Panjin could therefore attract a buyer, as Victrex's 2020 choice of Panjin shows.

  2. The IP portfolio has optional value. The four synthesis patents spanning PAEK and polysulfone resins could have licensing or sale value, provided they are still in force.

  3. Market conditions are now favourable. Monomer supply is expanding to about 11,000 t/y of fluoroketone, and the leader runs at full utilisation. That suggests a capable operator could today sell volumes that were unreachable in 2012.

Bear case (base case)

  1. The company is a non-operating shell. Licence revocation, recorded in December 2022, prevents lawful trading. No activity has been found for 2023–2026.

  2. It has been left behind on scale. Zhongyan is building to 11,000 t/y, and Victrex has 1,500 t/y in the same city. A dormant 1,000 t/y CoPEEK line with a single verified grade has no viable route back to competitiveness.

  3. Industry precedent points to exit. Kingfa, a far larger and better-capitalised company, also exited PEEK. Zhongyan itself cited both exits as evidence of high entry barriers.

Catalysts and monitorables (next 12 months)

MonitorableWhy it matters
SAMR / National Enterprise Credit Information Publicity System status change (revoked → deregistered, or reinstated)Confirms permanent exit or revival
Any court auction (司法拍卖) of Panjin assets or equipmentPossible asset transfer to a new entrant
Patent legal status on CNIPADetermines residual IP value
Ramp-up of Panjin Victrex XingfuShows the competitive intensity in the company's home cluster
Progress on Zhongyan's Zhangjiagang Phase 1Benchmark for domestic scale economics
SpecialChem/Omnexus listing removalSignals that the remaining commercial footprint has been abandoned

Concluding analyst verdict

Panjin Zhongrun High Performance Polymers is not an investable or currently operating company. It is best treated as a dormant, licence-revoked private entity. The input list's "public company" classification is wrong. The company never listed, never published financial statements, and has left almost no regulatory footprint. The single exception is a December 2022 STAR Market filing by its most successful rival, which cited it as an example of how hard PEEK synthesis is to commercialise.

The company's story is still instructive. Around 2009–2012 it got several strategic choices directionally right. It had a proven synthesis lineage from Jilin University, a differentiated copolymer brand, owned patents, a petrochemical-cluster location and an early European distributor. Its central error appears to have been timing and scale. It built about 1,000 t/y of nameplate capacity when all of China consumed under 100 t/y of PEEK. It then faced customer qualification cycles that can last up to two years, and incumbents that controlled the downstream stock-shape processors. Zhongyan ran the same chemistry at the same nameplate and used only 34–55% of its capacity as late as 2019–2021. It survived on a far broader product catalogue and a customer base anchored by large profile makers. Panjin Zhongrun, by contrast, has left evidence of only one commercial grade and no named customers.

Today the competitive gap is effectively unbridgeable. Zhongyan is building towards 11,000 t/y with integrated monomer supply, and Victrex has localised 1,500 t/y in Panjin itself. Any residual value is likely to lie in the site, its permits, or patents of uncertain legal status, and only if a new operator acquires them. Counterparties should verify the entity's current registry status directly through SAMR or Qichacha before any engagement. For exposure to Chinese PEEK through a listed vehicle, Jilin Zhongyan (688716.SH) is the appropriate subject of analysis.

Rating: Not rated / Not investable (inactive private entity).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenureSource

Steven Xu (徐, given name not disclosed)

Marketing and Sales Director

At least 2012

Plasteurope.com (3 May 2012)

Major Shareholders

HolderStakeSource

Shenyang Zhongrun Chemical (reported parent)

Not disclosed (described as the group the company belonged to)

Plasteurope (2012)

Institutional holders

Not applicable (unlisted)

—

Competitive Landscape

Key Competitors

#CompetitorCountryBrandCapacity (t/y)RouteRelative position vs. Panjin ZhongrunSource
1

Victrex plc

UK (LSE)

VICTREX

7,150 (2018–2021)

ICI nucleophilic

Global leader, >60% global share (per Zhongyan filing); dominant

Zhongyan IPO response (2022)

2

Syensqo (formerly Solvay Specialty Polymers)

Belgium

KetaSpire

~2,000 (2017 directory)

Gharda electrophilic

Tier-1 global

cmpe360 (2017)

3

Evonik Industries

Germany

VESTAKEEP

~500 in Changchun (2017 directory; since expanded)

Jilin University nucleophilic

Tier-1 global with a China plant

cmpe360 (2017); Process Worldwide

4

Jilin Zhongyan Polymer Materials (688716.SH)

China

ZYPEEK

1,000 (expanding by 10,000)

Jilin University nucleophilic

Domestic leader; about 8% global share per Northeast Securities (Feb 2024)

NESC (2024); CLS (2026)

5

Panjin Victrex Xingfu High Performance Materials (盘锦伟英兴)

China (Victrex 75%)

VICTREX

1,500 planned

ICI nucleophilic

Same city; foreign-majority local capacity

Zhongyan IPO response (2022)

6

Changchun Jida Tesu Engineering Research (吉大特塑)

China

—

100 PEEK (plus PEEKK, PEK, PES, PPSU at 100 each)

Jilin University nucleophilic

Small, broad portfolio

cmpe360 (2017)

7

Zhejiang Pengfulong (浙江鹏孚隆)

China

PFLUON

Expanding (not disclosed here)

—

Domestic tier-2

Zhongyan IPO response (2022); NESC (2024)

8

Shandong Haoran Tesu (山东浩然特塑)

China

———

Domestic tier-2

Zhongyan IPO response (2022)

9

Shandong Junhao High Performance Polymer (山东君昊), owned by Jiangsu Junhua

China

—

1,000 planned

—

Vertically integrated stock-shape maker moving upstream

Zhongyan IPO response (2022); Everbright (2023)

10

Kingfa Sci & Tech

China

VisPEEK

~300 (2017)

Jilin University nucleophilic

Exited PEEK per Zhongyan filing

cmpe360 (2017); Zhongyan IPO response (2022)

11

Jilin Juke, WOTE (沃特股份) and others

China

—

1,000 each planned

—

New entrants

Everbright Securities (Dec 2023)

“—” = not publicly disclosed.

Peer Comparison FY2021

MetricPanjin ZhongrunVictrexZhongyanSyensqo (KetaSpire)

PEEK nameplate capacity (t/y)

≤1,000 (historical)

7,150

1,000 (+10,000 planned)

~2,000 (2017)

Revenue

—

Group revenue < RMB 3 bn in 2021 (per Zhongyan filing)

RMB 203 M (FY2021)

Not split out

Revenue growth

—

+25.23% PEEK volume (2021, per Zhongyan filing)

34.70% CAGR (2019–2021)

Not split out

Gross margin

—

Not compiled here

44–53% by product (FY2021)

Not split out

R&D intensity

—

Not compiled here

Not compiled here

Not split out

Operating status

Licence revoked

Operating

Operating, full utilisation

Operating

“—” = not publicly disclosed.

Recent Developments

Twenty-five entries cannot be produced without fabrication. Each is labelled [Industry].

Company Snapshot

2009

Founded

Panjin, China

Headquarters

SWOT Analysis

Strengths

  • Owned IP across two polymer families. Four synthesis patents covering PSU, PES, PEES, PPSU and CoPEEK (cmpe360/Aibang, 2017).
  • Proven chemistry lineage. Used the Jilin University nucleophilic route, the same lineage as Zhongyan, Evonik-Changchun and Jida Tesu (cmpe360, 2017).
  • Large nameplate for its era. Up to 1,000 t/y, equal to the eventual domestic leader (Plasteurope, 2012; cmpe360, 2017).
  • Early export channel. Exclusive European distribution through Bieglo, showcased at Fakuma 2012 (Plasteurope, 2012).
  • Differentiated grade concept. A copolymer (CoPEEK) positioned on value-in-use, not commodity PEEK (Plasteurope, 2012).
  • Petrochemical-cluster location. Panjin hosts major petrochemical complexes and later attracted Victrex's PEEK JV (Zhongyan IPO response, 2022).

Weaknesses

  • Licence revoked. Cannot legally trade (Zhongyan/Da Hua SSE inquiry response, Dec 2022).
  • Unproven utilisation. Its operating rate was "unknown" even in a 2017 industry directory (cmpe360, 2017).
  • Capacity far ahead of demand. Capacity of 1,000 t/y against Chinese demand of 80–90 t in 2012–2013 (Zhongyan filing data).
  • Narrow catalogue. Only one verifiable grade (CoPEEK 085G), versus 52 grades at Zhongyan (SpecialChem; CNPP).
  • Zero public transparency. No financials, filings or named senior leadership beyond a sales director.
  • No verifiable downstream partnerships. No named stock-shape or OEM customers, in contrast to Zhongyan's disclosed top customers such as Ningbo Zheneng and Jiangsu Junhua.

Opportunities

  • Strong demand growth. China demand grew at a 42.84% CAGR in 2012–2021, with a forecast of 3,354 t by 2026 (CCIC, cited in Zhongyan filing).
  • Asset value to new entrants. More than 6,000 t/y of new domestic capacity was planned for 2023–2027 (Everbright Securities, Dec 2023). An existing permitted site could be attractive to buyers.
  • Monomer cost relief. About 11,000 t/y of Chinese fluoroketone capacity could support about 15,000 t/y of PEEK (NESC, Feb 2024).
  • Value of the polysulfone-family IP, if the patents are still in force.
  • Precedent for European distribution. Chinese PEEK makers are again signing European distributors (K.D. Feddersen / ZYPEEK).
  • Policy tailwinds. PEEK is treated as a strategic dual-use material (China Advanced Materials Expo commentary).

Threats

  • Scale race. Zhongyan is moving to 11,000 t/y with fluoroketone integration (CLS, May 2026).
  • Foreign capacity in the same city. Victrex's 1,500 t/y Panjin JV (Victrex, Jan 2020).
  • Precedent of exit. Kingfa exited PEEK, showing the difficulty even for well-funded entrants (Zhongyan IPO response, 2022).
  • Downstream integration. Customers are moving upstream into resin (Jiangsu Junhua → Shandong Junhao).
  • Trade friction. US tariffs cost Zhongyan its SABIC business, from RMB 6.13 M in 2020 to RMB 0.63 M in 2021 (Zhongyan filing).
  • Regulatory permanence. A revoked licence can lead to forced deregistration, and any revival requires remediation.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2025 (full year)Zhongyan's global PEEK sales exceed 1,000 t for the first timeThe same nameplate Zhongrun claimed is now fully used by the leader, showing that the market can absorb 1,000 t/y from one domestic player
14 May 2026 (evening)Zhongyan announces a RMB 1.2 bn integrated project in Zhangjiagang: 10,000 t/y PEEK plus 2,000 t/y PEEK raw materialsScale gap: the domestic leader is moving to 11,000 t/y total, plus fluoroketone integration
14 May 2026Signing ceremony for the Zhangjiagang project; local officials aim for "the most advanced" integrated PEEK base in ChinaPolicy support is concentrating on scaled leaders
15 May 2026Zhongyan's board office says the 1,000 t/y plant runs full year-round; the new project will be built in 2–3 phases over 2–3 years; profile (stock-shape) customers are its largest revenue shareConfirms that profile processors are the core demand base, the segment a CoPEEK producer would have targeted
2025–2026Market reports (Derwent, via Gelonghui) size the global PEEK special engineering plastics market at about US$700 M in 2026, rising to US$1,049 M by 2033 (5.95% CAGR)Panjin Zhongrun is still named in report tables of contents, but without verifiable data
2025–2026A separate report sizes the global "PEEK materials" market at about US$718 M in 2026, rising to US$1,163 M by 2033 (7.13% CAGR)Market definitions differ between reports
Undated, 2025–2026Zhongyan (as Jilin Joinature Polymer, ZYPEEK brand) appoints K.D. Feddersen as its European distributorChinese PEEK is again pursuing the European distribution model Zhongrun tried with Bieglo in 2012

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Margins & Profitability

1 chart
Margin Analysis (%): Coarse-powder capacity utilisation rose from 34.3% in FY2019 to 55% in FY2021.
Panjin Zhongrun High Performance Polymers Co., Ltd. — Margin Analysis (%)
Series (%)FY2019FY2020FY2021
Coarse-powder capacity utilisation34.354.155

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Plasteurope.com, "BIEGLO: Exclusive European distributor for Shandong Dongchen polyamides as well as Panjin Zhongrun's CoPEEK," 3 May 2012 (plasteurope.com)
  2. cmpe360 / Aibang Polymer (艾邦高分子), "全球7家特种塑料PEEK生产企业汇总," 29 Dec 2017 (cmpe360.com)
  3. Da Hua CPA / Jilin Zhongyan Polymer Materials, IPO inquiry response, "Description of financial matters" (大华核字[2022]0014516号), SSE disclosure, 7 Dec 2022 (static.sse.com.cn)
  4. SpecialChem / Omnexus, Panjin Zhongrun supplier page (CoPEEK 085G) (omnexus.specialchem.com)
  5. China Advanced Materials Industry Expo, "战略性军工材料—聚醚醚酮" (am-expo.net)
  6. Gelonghui (Derwent market reports, 2025–2026) · m.gelonghui.com · m.gelonghui.com · m.gelonghui.com
  7. Xinhua Finance / CNFIN, "中研股份聚醚醚酮(PEEK)一体化项目在江苏张家港签约," 16 May 2026 (cnfin.com)
  8. Cailian Press / STAR Market Daily, Zhongyan Zhangjiagang project, 15 May 2026 (cls.cn)
  9. Everbright Securities industry report on PEEK (Victrex case study), 3 Dec 2023 (pdf.dfcfw.com)
  10. Northeast Securities, Zhongyan (688716) initiation, 23 Feb 2024 (nesc.cn)
  11. ChemEngOnline, "Victrex creates JV in China for new PEEK plant," Jan 2020 (chemengonline.com)
  12. CHEManager, "Victrex Forms China Polymer JV," 16 Jan 2020 (chemanager-online.com)
  13. Plasteurope.com, "VICTREX: JV with Yingkou Xingfu to build PEEK plant in China," 21 Jan 2020 (plasteurope.com)
  14. chemie.de, Degussa–Jilin University PEEK/PES agreements (2004–2005) · chemie.de
  15. Process Worldwide, "Evonik To Expand Its PEEK Polymer Capacity" (Changchun, 2011) (process-worldwide.com)
  16. 21st Century Business Herald, Zhongyan STAR Market re-application, 22 Sep 2022 (m.sfccn.com)
  17. CNPP brand profile, Jilin Zhongyan (ZYPEEK) (cnpp.cn)
  18. 36Kr PitchHub, Zhongyan financing history (pitchhub.36kr.com)
  19. SPNews, "K.D. Feddersen Distribution expands portfolio" (ZYPEEK) (spnews.com)
  20. DirectIndustry / Taizhou Ark, "Specialty Plastics in China: Focus on PEEK Development" (trends.directindustry.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.